Reuters logo
BRIEF-Abivax says ABX196 efficacious in reducing tumor growth and increasing survival in preclinical model​
October 12, 2017 / 6:08 AM / 2 months ago

BRIEF-Abivax says ABX196 efficacious in reducing tumor growth and increasing survival in preclinical model​

Oct 12 (Reuters) - ABIVAX SA:

* ABIVAX PRESENTS NOVEL DATA ON THE EFFICACY OF ITS IMMUNE ENHANCER ABX196 IN ANIMAL MODEL OF LIVER CANCER AT THE WORLD VACCINE CONGRESS

* ‍ABX196 EFFICACIOUS IN REDUCING TUMOR GROWTH AND INCREASING SURVIVAL IN PRECLINICAL HEPATO-CELLULAR CANCER MODEL​

* ‍STRONG ENHANCEMENT OF IMMUNE RESPONSE IN LIVER TISSUE​

* ‍POTENTIAL SYNERGY WITH CHECKPOINT INHIBITORS (ANTI-PD-1)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below